Muscle volume loss after the induction of first-line chemotherapy as a novel prognostic factor in metastatic colorectal cancer patients

被引：0

作者：

Yoshikawa, Yusuke ^{[1
]}

Okabayashi, Koji ^{[1
]}

Hasegawa, Hirotoshi ^{[1
]}

Tsuruta, Masashi ^{[1
]}

Seishima, Ryo ^{[1
]}

Takahashi, Hidena ^{[1
]}

Yamada, Toru ^{[1
]}

Matsui, Shimpei ^{[1
]}

Kondo, Takayuki ^{[1
]}

Shimada, Takehiro ^{[1
]}

Matsuda, Mutsuhito ^{[1
]}

Yahagi, Masashi ^{[1
]}

Asada, Yusuke ^{[1
]}

Sugiura, Kiyoaki ^{[1
]}

Suzuki, Yoshiyuki ^{[1
]}

Tajima, Yuki ^{[1
]}

Nakadai, Junpei ^{[1
]}

Kitagawa, Yuko ^{[1
]}

机构：

[1] Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期

关键词：

D O I：

10.1200/jco.2015.33.3_suppl.558

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

558

引用

页数：1

共 50 条

[1] Neutropenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
Shitara, K.
Matsuo, K.
Takahari, D.
Yokota, T.
Ura, T.
Muro, K.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[2] Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
Shitara, Kohei
Matsuo, Keitaro
Takahari, Daisuke
Yokota, Tomoya
Inaba, Yoshitaka
Yamaura, Hidekazu
Sato, Yozo
Najima, Mina
Ura, Takashi
Muro, Kei
EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) : 1757 - 1763
[3] Capecitabine Maintenance Therapy after First-Line Chemotherapy in Patients with Metastatic Colorectal Cancer
Yan Li
Department of GI Oncology
Chinese Journal of Cancer Research, 2010, 22 (03) : 181 - 185
[4] Capecitabine Maintenance Therapy after First-Line Chemotherapy in Patients with Metastatic Colorectal Cancer
Li, Yan
Li, Jing
Lu, Ming
Wang, Xi-cheng
Shen, Lin
CHINESE JOURNAL OF CANCER RESEARCH, 2010, 22 (03) : 181 - 185
[5] Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
Bousahba, A.
Behourah, Z.
ANNALS OF ONCOLOGY, 2019, 30
[6] Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy
Tada, K.
Shoji, H.
Kitano, S.
Nishimura, T.
Shimada, Y.
Nagashima, K.
Ito, A.
Honma, Y.
Iwasa, S.
Okita, N.
Takashima, A.
Kato, K.
Yamada, Y.
Katayama, N.
Boku, N.
Heike, Y.
Hamaguchi, T.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S80 - S80
[7] Place of first-line palliative chemotherapy in patients with metastatic colorectal cancer
Hebbar, M
REVUE DE MEDECINE INTERNE, 1997, 18 : S364 - S367
[8] Sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy
Maddalena, C.
Ponsiglione, A.
Camera, L.
Santarpia, L.
Pasanisi, F.
Bruzzese, D.
Panico, C.
Fiore, G.
Camardella, S.
Caramia, T.
Farinaro, A.
De Placido, S.
Carlomagno, C.
ANNALS OF ONCOLOGY, 2020, 31 : S178 - S178
[9] Optimizing first-line chemotherapy for metastatic colorectal cancer
Adams, Richard A.
COLORECTAL CANCER, 2012, 1 (03) : 241 - 253
[10] Efficacy of second-line chemotherapy after a first-line triplet in patients with metastatic colorectal cancer
Bazarbashi, S.
Hakoun, A. M.
Gad, A. M.
Elshenawy, M. A.
Aljubran, A.
Alzahrani, A. M.
Eldali, A.
CURRENT ONCOLOGY, 2019, 26 (01) : E24 - E29

← 1 2 3 4 5 →